Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸¸¼º ÄáÆϺ´ ȯÀÚ¿¡¼­ °ñ´Ù°øÁõ Osteoporosis in Patients with Chronic Kidney Disease

´ëÇѳ»°úÇÐȸÁö 2020³â 95±Ç 2È£ p.89 ~ 94
±Ç¿µÁÖ,
¼Ò¼Ó »ó¼¼Á¤º¸
±Ç¿µÁÖ ( Kwon Young-Joo ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ½ÅÀå³»°ú

Abstract


Osteoporosis in chronic kidney disease (CKD) is also referred to as ¡®CKD with low bone mineral density (BMD)¡¯, because the cause of low BMD in CKD includes chronic kidney disease-mineral bone disorders (CKD-MBD) such as secondary hyperparathyroidism, osteomalacia, and adynamic bone disease. Diagnostic methods of osteoporosis in CKD include FRAX¢ç, BMD, and bone turnover markers as well as CKD-MBD biochemical parameters- calcium, P, alkaline phosphatase, PTH, and 25(OH)D3. The management of osteoporosis in CKD prioritizes CKD-MBD management over selection of bone anti-resorptive agents or osteo-anabolic agents according to clinical and laboratory findings.

Å°¿öµå

Chronic kidney failure; Chronic kidney insufficiency; Osteoporosis; Chronic kidney disease mineral bone disorder

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS